The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia

Abstract Medication nonadherence in schizophrenia can have serious implications including relapses and hospitalization. Long-acting injectable (LAI) antipsychotics require fewer administrations, while ensuring sustained medication coverage. In this review, we summarize the expected real-world benefits of longer dosing intervals in the management of schizophrenia. LAIs are associated with improved clinical outcomes of less frequent relapses and reduced functional impairment, encouraging patients to regain control of their lives. Aripiprazole lauroxil and paliperidone palmitate three-monthly (PP3M) LAIs have longer dosing intervals of 2–3 months and provide improved outcomes in patients with schizophrenia. Paliperidone palmitate six-monthly (PP6M) LAI provides the longest dosing interval, twice-yearly dosing, among existing LAIs. Decreasing the frequency of LAI administrations has the potential to reduce occurrence of serious outcomes associated with poor medication adherence. By eliminating the need for daily oral antipsychotic dosing, LAIs could increase the likelihood of patient acceptance, decrease stigma, and promote self-esteem. Longer intervals of medication coverage may be desirable for patients with higher risk of relapse including adults with recent-onset schizophrenia, those living in circumstances that may deprive them of regular access (eg, homeless), those that are in transitions between care settings or to reduce interpersonal contact during public health emergencies (eg, COVID-19 pandemic).

[1]  T. Furukawa,et al.  Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis , 2022, The Lancet.

[2]  C. Correll,et al.  The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach , 2022, BMC Psychiatry.

[3]  M. García-Portilla,et al.  Impact on functionality of the paliperidone palmitate three-month formulation in patients with a recent diagnosis of schizophrenia: a real-world observational prospective study , 2022, Expert opinion on pharmacotherapy.

[4]  L. Citrome,et al.  Perceived Burdens and Educational Needs of Caregivers of People with Schizophrenia: Results of a National Survey Study , 2022, Patient preference and adherence.

[5]  David Taylor,et al.  Effect of 3-monthly paliperidone palmitate on hospitalisation in a naturalistic schizophrenia cohort - A five-year mirror image study. , 2022, Journal of psychiatric research.

[6]  J. McEvoy,et al.  Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia , 2021, CNS Drugs.

[7]  P. Mavros,et al.  Correction to: Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis , 2021, CNS Drugs.

[8]  A. Tanskanen,et al.  Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study. , 2021, Schizophrenia bulletin.

[9]  N. Tandon,et al.  Long-Acting Injectable Antipsychotic Use in Patients with Schizophrenia and Criminal Justice System Encounters , 2021, Journal of health economics and outcomes research.

[10]  T. Kishimoto,et al.  Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. , 2021, The lancet. Psychiatry.

[11]  O. Tcheremissine,et al.  The Impact of Once-Monthly Paliperidone Palmitate on Healthcare Utilization Among Patients With Schizophrenia Treated in an Integrated Healthcare System: A Retrospective Mirror-Image Study , 2021, Advances in Therapy.

[12]  R. Lencer,et al.  Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate. , 2021, Comprehensive psychiatry.

[13]  P. Lefebvre,et al.  Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries with Prior Schizophrenia Relapse. , 2021, Clinical therapeutics.

[14]  P. Lefebvre,et al.  Medication adherence, healthcare resource utilization, and costs among Medicaid beneficiaries with schizophrenia treated with once-monthly paliperidone palmitate or once-every-three-months paliperidone palmitate , 2021, Current medical research and opinion.

[15]  Edward Kim,et al.  Risk of subsequent relapses and corresponding healthcare costs among recently-relapsed Medicaid patients with schizophrenia: a real-world retrospective cohort study , 2021, Current medical research and opinion.

[16]  S. Pappa,et al.  Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate , 2021, Therapeutic advances in psychopharmacology.

[17]  A. Vita,et al.  The Patient, Investigator, Nurse, Carer Questionnaire (PINC-Q): a cross-sectional, retrospective, non-interventional study exploring the impact of less frequent medication administration with paliperidone palmitate 3-monthly as maintenance treatment for schizophrenia , 2020, BMC Psychiatry.

[18]  OUP accepted manuscript , 2021, The International Journal of Neuropsychopharmacology.

[19]  J. García-Carmona,et al.  Evaluation of long-acting injectable antipsychotics with the corresponding oral formulation in a cohort of patients with schizophrenia: a real-world study in Spain , 2020, International clinical psychopharmacology.

[20]  J. Lieberman,et al.  How mental health care should change as a consequence of the COVID-19 pandemic , 2020, The Lancet Psychiatry.

[21]  P. Weiden,et al.  Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study , 2020, CNS Drugs.

[22]  M. Mathews,et al.  Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire , 2020, Patient preference and adherence.

[23]  M. Mathews,et al.  Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies , 2020, Neuropsychiatric disease and treatment.

[24]  Jessica M. Gannon,et al.  Long acting injectable antipsychotic medications: Ensuring care continuity during the COVID-19 pandemic restrictions , 2020, Schizophrenia Research.

[25]  P. Llorca,et al.  Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia , 2020, Therapeutic advances in psychopharmacology.

[26]  L. Dima,et al.  Long-acting injectable antipsychotics treatment during COVID-19 pandemic – A new challenge , 2020, Schizophrenia Research.

[27]  O. Howes,et al.  Schizophrenia-An Overview. , 2020, JAMA psychiatry.

[28]  P. Lefebvre,et al.  Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate , 2019, Drugs - Real World Outcomes.

[29]  Seung Woo Cho,et al.  Continuation of schizophrenia treatment with three long-acting injectable antipsychotics in South Korea: A nationwide population-based study , 2019, European Neuropsychopharmacology.

[30]  P. Czobor,et al.  Comparative effectiveness of second generation long-acting injectable antipsychotics based on nationwide database research in Hungary , 2019, PloS one.

[31]  C. Correll,et al.  Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia , 2019, Neuropsychiatric disease and treatment.

[32]  J. Dilley,et al.  Recovery-Oriented Outcomes Associated with Long-Acting Injectable Antipsychotics in an Urban Safety-Net Population , 2019, Community Mental Health Journal.

[33]  A. Ballerini,et al.  The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia , 2019, Neuropsychiatric disease and treatment.

[34]  M. Broder,et al.  Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data , 2019, Current medical research and opinion.

[35]  P. Lefebvre,et al.  Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans , 2019, Current medical research and opinion.

[36]  M. Bernardo,et al.  The current data on the 3-month paliperidone palmitate formulation for the treatment of schizophrenia , 2018, Expert opinion on pharmacotherapy.

[37]  M. Broder,et al.  Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data , 2018, Advances in Therapy.

[38]  B. Shiner,et al.  Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans. , 2018, Clinical therapeutics.

[39]  M. Byerly,et al.  Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2 , 2018, Neuropsychiatric disease and treatment.

[40]  P. Ferri,et al.  Clinical improvement, relapse and treatment adherence with paliperidone palmitate 1-month formulation: 1-year treatment in a naturalistic outpatient setting , 2018, Nordic journal of psychiatry.

[41]  Yongling Xiao,et al.  Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics , 2018, Journal of medical economics.

[42]  A. Tanskanen,et al.  Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia , 2017, Schizophrenia Research.

[43]  M. Sajatovic,et al.  A 6-Month Prospective Trial of a Personalized Behavioral Intervention + Long-Acting Injectable Antipsychotic in Individuals With Schizophrenia at Risk of Treatment Nonadherence and Homelessness , 2017, Journal of clinical psychopharmacology.

[44]  P. Bozzatello,et al.  Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia , 2017, Neuropsychiatric disease and treatment.

[45]  P. Lefebvre,et al.  Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics. , 2017, Clinical therapeutics.

[46]  P. Weiden,et al.  Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone. , 2017, The Journal of clinical psychiatry.

[47]  P. Lefebvre,et al.  Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting , 2017, Current medical research and opinion.

[48]  Jingping Zhao,et al.  Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study , 2017, Neuropsychiatric disease and treatment.

[49]  M. Mathews,et al.  Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies , 2017, npj Schizophrenia.

[50]  P. Weiden,et al.  Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model , 2017, CNS Drugs.

[51]  B. Shiner,et al.  Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans with Schizophrenia. , 2016, The Journal of clinical psychiatry.

[52]  Xiaoyun Pan,et al.  Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate , 2016, Current medical research and opinion.

[53]  X. Haiyan,et al.  PM511. Determinants of Caregiver Burden in Family Carers of Asian Patients with Schizophrenia treated with Paliperidone Palmitate 3-monthly injectable , 2016, International Journal of Neuropsychopharmacology.

[54]  P. Rocca,et al.  Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life , 2016, Neuropsychiatric disease and treatment.

[55]  W. Fleischhacker,et al.  Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study , 2016, The international journal of neuropsychopharmacology.

[56]  L. Alphs,et al.  A pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophrenia , 2016, Schizophrenia Research.

[57]  R. Risinger,et al.  A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. , 2015, The Journal of clinical psychiatry.

[58]  Yanning Liu,et al.  Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial. , 2015, JAMA psychiatry.

[59]  J. Lindenmayer,et al.  Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. , 2015, The Journal of clinical psychiatry.

[60]  M. Mimura,et al.  A review on schizophrenia and relapse—a quest for user‐friendly psychopharmacotherapy , 2014, Human psychopharmacology.

[61]  P. Weiden,et al.  Comparison of Olanzapine Long-Acting Injection and Oral Olanzapine: A 2-Year, Randomized, Open-Label Study in Outpatients With Schizophrenia , 2014, Journal of clinical psychopharmacology.

[62]  David Taylor,et al.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal , 2014, Therapeutic advances in psychopharmacology.

[63]  V. Cornelius,et al.  Paliperidone palmitate long‐acting injection – prospective year‐long follow‐up of use in clinical practice , 2014, Acta psychiatrica Scandinavica.

[64]  R. Rosenheck,et al.  Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. , 2014, JAMA.

[65]  Lange Ap,et al.  History and therapeutic rationale of long acting antipsychotics. , 2014 .

[66]  A. de Risio,et al.  History and therapeutic rationale of long acting antipsychotics. , 2014, Current clinical pharmacology.

[67]  Hassan Khan,et al.  Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. , 2013, European heart journal.

[68]  Stephan Heckers,et al.  Definition and description of schizophrenia in the DSM-5 , 2013, Schizophrenia Research.

[69]  W. Fleischhacker,et al.  Long-Acting Injectable Formulations of New-Generation Antipsychotics: A Review from a Clinical Perspective , 2013, CNS Drugs.

[70]  J. Kane,et al.  Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia , 2013, Journal of medical economics.

[71]  P. Fusar-Poli,et al.  Patients’ and clinicians’ attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis , 2013, Therapeutic advances in psychopharmacology.

[72]  Erika P. Raven,et al.  Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia , 2012, Schizophrenia Research.

[73]  R. Hansen,et al.  Adherence to antipsychotics and cardiometabolic medication: association with health care utilization and costs. , 2012, Psychiatric services.

[74]  Michael F. Green,et al.  Functional impairment in people with schizophrenia: Focus on employability and eligibility for disability compensation , 2012, Schizophrenia Research.

[75]  R. Hansen,et al.  Antipsychotic adherence and its correlation to health outcomes for chronic comorbid conditions. , 2012, The primary care companion for CNS disorders.

[76]  E. Mundo,et al.  Intramuscular Preparations of Antipsychotics , 2012, Drugs.

[77]  Erika P. Raven,et al.  Long acting injection versus oral risperidone in first-episode schizophrenia: Differential impact on white matter myelination trajectory , 2011, Schizophrenia Research.

[78]  J. Volavka,et al.  Pathways to aggression in schizophrenia affect results of treatment. , 2011, Schizophrenia bulletin.

[79]  S. Fazel,et al.  Psychotic disorders and repeat offending: systematic review and meta-analysis. , 2011, Schizophrenia bulletin.

[80]  J. Tiihonen,et al.  A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. , 2011, The American journal of psychiatry.

[81]  S. Gopal,et al.  A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia , 2011, Journal of psychopharmacology.

[82]  R. Rosenheck,et al.  Criminal Justice System Involvement Among People with Schizophrenia , 2011, Community Mental Health Journal.

[83]  S. Gopal,et al.  Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study , 2010, International clinical psychopharmacology.

[84]  Josep Maria Haro,et al.  Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia , 2010, Psychiatry Research.

[85]  J. Kane,et al.  Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. , 2010, The American journal of psychiatry.

[86]  S. Gopal,et al.  Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study , 2010, Schizophrenia Research.

[87]  B. Eriksson,et al.  The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden , 2010, The European Journal of Health Economics.

[88]  David Taylor.  Psychopharmacology and adverse effects of antipsychotic long-acting injections: A review , 2009, British Journal of Psychiatry.

[89]  Mark Taylor,et al.  Attitudes of patients and mental health staff to antipsychotic long-acting injections: Systematic review , 2009, British Journal of Psychiatry.

[90]  J. Lauriello,et al.  An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. , 2008, The Journal of clinical psychiatry.

[91]  L. Hranov,et al.  Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial , 2008, The Lancet.

[92]  A. Fu,et al.  Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States , 2007, Current medical research and opinion.

[93]  I. Glick,et al.  Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. , 2005, The Journal of clinical psychiatry.

[94]  Jürgen Unützer,et al.  Prevalence and risk factors for homelessness and utilization of mental health services among 10,340 patients with serious mental illness in a large public mental health system. , 2005, The American journal of psychiatry.

[95]  P. Chue,et al.  Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets , 2005, European Neuropsychopharmacology.

[96]  M. Knapp,et al.  Relapse in schizophrenia: costs, clinical outcomes and quality of life , 2004, British Journal of Psychiatry.

[97]  E. Mundo,et al.  Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. , 2003, Drugs.

[98]  Christian R. Dolder,et al.  Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. , 2002, The Journal of clinical psychiatry.

[99]  L. Teplin.  The prevalence of severe mental disorder among male urban jail detainees: comparison with the Epidemiologic Catchment Area Program. , 1990, American journal of public health.

[100]  G. Klerman,et al.  Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate. , 1980, Archives of general psychiatry.

[101]  F. Quitkin,et al.  Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year. , 1977, Archives of general psychiatry.